[1] Floreani A,Mangini C. Primary biliary cholangitis: old and novel therapy. Eur J Intern med,2018,47:1-5.
[2] Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med,2016,375:631-643.
[3] Wong LL, Hegade VS, Jones DEJ. What comes after ursode-oxycholic acid in primary biliary cholangitis.Dig Dis (Basel,Switzerland),2017,35:359-366.
[4] Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood,1994,83:435-445.
[5] Khanna A, Jopson L, Howel D, et al. Rituximab is ineffective for treatment of fatigue in primary biliary cholangitis: a phase 2 randomized controlled trial. Hepatology (Baltimore, Md.), 2018, 70:1646-1657
[6] Beuers U , Hohenester S. Fatigue in Primary Biliary Cholangitis: no place for rituximab. Hepatology,2019,70:1503-1505.
[7] Myers RP, Swain MG, Lee SS, et al. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastroenterol,2013,108:933-941.
[8] Khanna A, Jopson L, Howel D,et al. Rituximab for the treatment of fatigue in primary biliary cholangitis (formerly primary biliary cirrhosis): a randomised controlled trial. Southampton (UK): NIHR Journals Library,2018 Apr.
[9] Tsuda M, Moritoki Y, Lian ZX, et al. Biochemical and imm-unologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology,2012,55:512-521. |
